Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

M. C. Robson, Linda Phillips, L. E. Robson, A. Thomason, G. F. Pierce

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

Original languageEnglish (US)
Pages (from-to)23-25
Number of pages3
JournalThe Lancet
Volume339
Issue number8784
DOIs
StatePublished - Jan 4 1992

Fingerprint

Pressure Ulcer
Placebos
Ulcer
Therapeutics
Poisons
Wound Healing
platelet-derived growth factor BB

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. / Robson, M. C.; Phillips, Linda; Robson, L. E.; Thomason, A.; Pierce, G. F.

In: The Lancet, Vol. 339, No. 8784, 04.01.1992, p. 23-25.

Research output: Contribution to journalArticle

Robson, M. C. ; Phillips, Linda ; Robson, L. E. ; Thomason, A. ; Pierce, G. F. / Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. In: The Lancet. 1992 ; Vol. 339, No. 8784. pp. 23-25.
@article{129e7ae913b14c1184d1e3f87853f172,
title = "Platelet-derived growth factor BB for the treatment of chronic pressure ulcers",
abstract = "A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]{\%} of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.",
author = "Robson, {M. C.} and Linda Phillips and Robson, {L. E.} and A. Thomason and Pierce, {G. F.}",
year = "1992",
month = "1",
day = "4",
doi = "10.1016/0140-6736(92)90143-Q",
language = "English (US)",
volume = "339",
pages = "23--25",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8784",

}

TY - JOUR

T1 - Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

AU - Robson, M. C.

AU - Phillips, Linda

AU - Robson, L. E.

AU - Thomason, A.

AU - Pierce, G. F.

PY - 1992/1/4

Y1 - 1992/1/4

N2 - A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

AB - A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

UR - http://www.scopus.com/inward/record.url?scp=0026595966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026595966&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(92)90143-Q

DO - 10.1016/0140-6736(92)90143-Q

M3 - Article

C2 - 1345953

AN - SCOPUS:0026595966

VL - 339

SP - 23

EP - 25

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8784

ER -